Pub Date : 2025-02-10DOI: 10.3390/medicina61020301
Sergiu Ioan Murg, Loredana Matiș, Andrada Florina Moldovan, Dorel Ionel Popovici, Alina Gabriela Negru, Timea Claudia Ghitea, Mircea Ioachim Popescu
Background and Objectives: Cardio-oncology addresses the growing concern of cardiovascular complications arising from cancer therapies. Although cancer treatments have greatly enhanced survival outcomes, they frequently carry substantial risks to cardiovascular health. This research examines the cardiovascular toxicity associated with HER2-targeted therapies, focusing on the interconnection between tumor characteristics, including histopathological profiles and TNM classification, and the development of cardiovascular complications. The objective is to identify key correlations that inform better prevention and management strategies for cardiotoxicity in oncology patients. Materials and Methods: This retrospective study analyzed cancer patients undergoing cytostatic treatments, particularly anthracyclines, radiotherapy, and HER2-targeted therapies. Cardiac function was monitored using echocardiographic assessments, including global longitudinal strain and left ventricular ejection fraction (LVEF). Patients were stratified based on TNM cancer staging and histopathological findings to evaluate correlations between treatment regimens and cardiovascular outcomes. Results: The analysis revealed a significant association between advanced TNM stages and reduced LVEF, with patients in stage T4 showing the highest prevalence of cardiac dysfunction. Cytostatic treatments, such as anthracyclines and HER2-targeted therapies, were identified as key contributors to cardiotoxicity, particularly in advanced-stage cancer patients. These findings emphasize the importance of regular cardiac monitoring to detect early signs of cardiotoxicity, as patients with pre-existing cardiovascular risk factors demonstrated a higher prevalence of complications. Conclusions: This study highlights the need for personalized treatment approaches and tailored cardioprotective strategies to improve outcomes and enhance the quality of life for oncology patients. Future studies should prioritize developing improved strategies to reduce the cardiovascular complications linked to contemporary cancer treatments.
{"title":"Association Between Advanced TNM Stages and Increased Risk of Cardiac Dysfunction in Patients with LVEF < 50.","authors":"Sergiu Ioan Murg, Loredana Matiș, Andrada Florina Moldovan, Dorel Ionel Popovici, Alina Gabriela Negru, Timea Claudia Ghitea, Mircea Ioachim Popescu","doi":"10.3390/medicina61020301","DOIUrl":"10.3390/medicina61020301","url":null,"abstract":"<p><p><i>Background and Objectives:</i> Cardio-oncology addresses the growing concern of cardiovascular complications arising from cancer therapies. Although cancer treatments have greatly enhanced survival outcomes, they frequently carry substantial risks to cardiovascular health. This research examines the cardiovascular toxicity associated with HER2-targeted therapies, focusing on the interconnection between tumor characteristics, including histopathological profiles and TNM classification, and the development of cardiovascular complications. The objective is to identify key correlations that inform better prevention and management strategies for cardiotoxicity in oncology patients. <i>Materials and Methods:</i> This retrospective study analyzed cancer patients undergoing cytostatic treatments, particularly anthracyclines, radiotherapy, and HER2-targeted therapies. Cardiac function was monitored using echocardiographic assessments, including global longitudinal strain and left ventricular ejection fraction (LVEF). Patients were stratified based on TNM cancer staging and histopathological findings to evaluate correlations between treatment regimens and cardiovascular outcomes. <i>Results:</i> The analysis revealed a significant association between advanced TNM stages and reduced LVEF, with patients in stage T4 showing the highest prevalence of cardiac dysfunction. Cytostatic treatments, such as anthracyclines and HER2-targeted therapies, were identified as key contributors to cardiotoxicity, particularly in advanced-stage cancer patients. These findings emphasize the importance of regular cardiac monitoring to detect early signs of cardiotoxicity, as patients with pre-existing cardiovascular risk factors demonstrated a higher prevalence of complications. <i>Conclusions:</i> This study highlights the need for personalized treatment approaches and tailored cardioprotective strategies to improve outcomes and enhance the quality of life for oncology patients. Future studies should prioritize developing improved strategies to reduce the cardiovascular complications linked to contemporary cancer treatments.</p>","PeriodicalId":49830,"journal":{"name":"Medicina-Lithuania","volume":"61 2","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11857368/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143505550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-10DOI: 10.3390/medicina61020305
Clement Tan, Mark Daniel Higgins, Vaikunthan Thanabalasingam, Chaminda Sella Kapu, Zhihua Zhang
Stroke is a devastating complication of cardiovascular interventions. Intraprocedural stroke is a well-documented and feared risk of cardiac percutaneous transcatheter procedures. If clinically significant strokes are absent, silent strokes remain the next in line to pose large concerns related to future cognitive decline, stroke risk, and overall increased morbidity and mortality. Cerebral protection devices (CPD) developed overtime aim to neutralize this risk through either a capture-based filter or a deflector mechanism. Many CPDs exist currently, each one unique, with varying degrees of evidence. The adoption of CPDs has allowed cardiac percutaneous transcatheter procedures to be carried out in patients with high thromboembolic risks who may have historically been discommended. Though skewed towards certain devices and transcatheter procedures, a large body of evidence is still present across other devices and procedures. This review will discuss clinical importance and respective stroke rates, updated evidence surrounding CPDs, differing opinions across types of CPDs, cost benefits, and what lies ahead for CPDs within the realm of procedures undertaken in cardiac catheterization laboratories.
{"title":"Neuroprotection Devices in Cardiac Catheterization Laboratories: Does It Sufficiently Protect Our Patients?","authors":"Clement Tan, Mark Daniel Higgins, Vaikunthan Thanabalasingam, Chaminda Sella Kapu, Zhihua Zhang","doi":"10.3390/medicina61020305","DOIUrl":"10.3390/medicina61020305","url":null,"abstract":"<p><p>Stroke is a devastating complication of cardiovascular interventions. Intraprocedural stroke is a well-documented and feared risk of cardiac percutaneous transcatheter procedures. If clinically significant strokes are absent, silent strokes remain the next in line to pose large concerns related to future cognitive decline, stroke risk, and overall increased morbidity and mortality. Cerebral protection devices (CPD) developed overtime aim to neutralize this risk through either a capture-based filter or a deflector mechanism. Many CPDs exist currently, each one unique, with varying degrees of evidence. The adoption of CPDs has allowed cardiac percutaneous transcatheter procedures to be carried out in patients with high thromboembolic risks who may have historically been discommended. Though skewed towards certain devices and transcatheter procedures, a large body of evidence is still present across other devices and procedures. This review will discuss clinical importance and respective stroke rates, updated evidence surrounding CPDs, differing opinions across types of CPDs, cost benefits, and what lies ahead for CPDs within the realm of procedures undertaken in cardiac catheterization laboratories.</p>","PeriodicalId":49830,"journal":{"name":"Medicina-Lithuania","volume":"61 2","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11857601/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143505225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-09DOI: 10.3390/medicina61020299
Katarzyna Błochowiak, Aya Kraiz, Monika Bowszyc-Dmochowska, Elżbieta Paszyńska, Dorota Jenerowicz
Miescher's cheilitis (MC) is a rare, idiopathic inflammatory condition marked by recurrent or persistent swelling of the lips and adjacent orofacial areas. This case study aims to explore the clinical presentation of Miescher's cheilitis and evaluate the effectiveness of intralesional corticosteroid therapy as a treatment approach. A 58-year-old male presented with severe, persistent swelling of both the upper and lower lips, which had been ongoing for six months. The initial treatment with chloroquine was discontinued due to adverse effects and no efficacy. Subsequent treatment involved intralesional injections of triamcinolone acetonide, administered at concentrations of 10 mg/mL and 40 mg/mL. After a total of ten injection sessions, the patient experienced a nearly 70% reduction in lip swelling, with the therapeutic effect lasting for 9 months. Intralesional corticosteroid therapy proved to be an effective treatment for Miescher's cheilitis, offering significant symptom relief and improvement in lip swelling when other treatments were ineffective or unsuitable. This case highlights the need for individualized treatment plans and underscores the importance of ongoing research to refine management strategies for this challenging condition.
{"title":"Miescher's Cheilitis as a Diagnostic and Therapeutic Challenge-A Case Report.","authors":"Katarzyna Błochowiak, Aya Kraiz, Monika Bowszyc-Dmochowska, Elżbieta Paszyńska, Dorota Jenerowicz","doi":"10.3390/medicina61020299","DOIUrl":"10.3390/medicina61020299","url":null,"abstract":"<p><p>Miescher's cheilitis (MC) is a rare, idiopathic inflammatory condition marked by recurrent or persistent swelling of the lips and adjacent orofacial areas. This case study aims to explore the clinical presentation of Miescher's cheilitis and evaluate the effectiveness of intralesional corticosteroid therapy as a treatment approach. A 58-year-old male presented with severe, persistent swelling of both the upper and lower lips, which had been ongoing for six months. The initial treatment with chloroquine was discontinued due to adverse effects and no efficacy. Subsequent treatment involved intralesional injections of triamcinolone acetonide, administered at concentrations of 10 mg/mL and 40 mg/mL. After a total of ten injection sessions, the patient experienced a nearly 70% reduction in lip swelling, with the therapeutic effect lasting for 9 months. Intralesional corticosteroid therapy proved to be an effective treatment for Miescher's cheilitis, offering significant symptom relief and improvement in lip swelling when other treatments were ineffective or unsuitable. This case highlights the need for individualized treatment plans and underscores the importance of ongoing research to refine management strategies for this challenging condition.</p>","PeriodicalId":49830,"journal":{"name":"Medicina-Lithuania","volume":"61 2","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11857799/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143505694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-09DOI: 10.3390/medicina61020302
Harun Muğlu, Erdem Sünger, Bahadır Köylü, Didem Tunalı, Cengiz Erol, Fatih Selcukbiricik, Ahmet Bilici, Omer Fatih Olmez
Immune checkpoint inhibitors (ICIs) therapy has revolutionized cancer treatment. However, it is important to acknowledge that ICI therapy can lead to immune-related adverse events (irAEs), including myocarditis. While early-onset myocarditis is well-documented, late-onset cases are increasingly recognized. This case series presents four cases of late-onset ICI-associated myocarditis, emphasizing the need for long-term surveillance of this potentially fatal complication. Patients exhibited a range of cardiac symptoms, including chest pain, shortness of breath, and arrhythmias. The diagnosis was confirmed through cardiac magnetic resonance imaging (MRI) and elevated cardiac biomarkers. Treatment involved the immediate discontinuation of ICI therapy and the initiation of high-dose corticosteroids. In cases with an inadequate response, additional immunosuppressive agents were considered. This case series underscores the importance of prolonged monitoring for late-onset ICI-associated myocarditis. Further research is needed to establish optimal treatment strategies and long-term management approaches for this complex condition.
{"title":"Late-Onset Myocarditis Following Immune Checkpoint Inhibitors Therapy: A Case Series with Literature Review.","authors":"Harun Muğlu, Erdem Sünger, Bahadır Köylü, Didem Tunalı, Cengiz Erol, Fatih Selcukbiricik, Ahmet Bilici, Omer Fatih Olmez","doi":"10.3390/medicina61020302","DOIUrl":"10.3390/medicina61020302","url":null,"abstract":"<p><p>Immune checkpoint inhibitors (ICIs) therapy has revolutionized cancer treatment. However, it is important to acknowledge that ICI therapy can lead to immune-related adverse events (irAEs), including myocarditis. While early-onset myocarditis is well-documented, late-onset cases are increasingly recognized. This case series presents four cases of late-onset ICI-associated myocarditis, emphasizing the need for long-term surveillance of this potentially fatal complication. Patients exhibited a range of cardiac symptoms, including chest pain, shortness of breath, and arrhythmias. The diagnosis was confirmed through cardiac magnetic resonance imaging (MRI) and elevated cardiac biomarkers. Treatment involved the immediate discontinuation of ICI therapy and the initiation of high-dose corticosteroids. In cases with an inadequate response, additional immunosuppressive agents were considered. This case series underscores the importance of prolonged monitoring for late-onset ICI-associated myocarditis. Further research is needed to establish optimal treatment strategies and long-term management approaches for this complex condition.</p>","PeriodicalId":49830,"journal":{"name":"Medicina-Lithuania","volume":"61 2","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11857675/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143505626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-09DOI: 10.3390/medicina61020300
Juquan Song, George Golovko, Kostiantyn Botnar, Amina El Ayadi, Kathleen L Vincent, Steven E Wolf
Background and Objectives: Postmenopausal women are often treated with exogenous female hormones to alleviate physical symptoms and support mental health. We posit that women treated with estrogen fare better following burn injury. Materials and Methods: De-identified patient data were obtained from TriNetX, a global healthcare research network. Adult postmenopausal women were enrolled if they were diagnosed with burn injury within 10 years after menopause onset. Patients with pre-existing abnormal uterine bleeding, gynecologic cancer, and chronic liver or heart disease were excluded. The population was grouped into those who received and those who did not receive estrogen treatment (ET) for evaluation of subsequent complications. Cohort balancing was performed using the exact match approach of Inverse Probability Treatment Weighting (IPTW). The average treatment effects (ATEs) and confidence intervals were computed for these balanced cohorts. Results: Postmenopausal women with ET had a lower risk of endometrial hyperplasia and malignancy 3 months (ATE = -0.005, -0.006) and 3 years (-0.007, -0.008) after mild burn injury (less than 20% of total body surface area) (p < 0.05), regardless of age. At the 3-month timepoint, postmenopausal women aged 45-65 with ET exhibited preventive effects against acute kidney injury (-0.0332), cerebral infarction (-0.0279), breast cancer (-0.0278) and severe sepsis (-0.011) after mild burn injury (p < 0.05) compared to women who did not receive ET. After 3 years, 45-65-year-old women with ET exhibited decreased rates of breast cancer (-0.0479) and endometrial hyperplasia (-0.0116) (p < 0.05) compared to those without ET. Conclusions: Estrogen treatment decreases the risk probabilities of breast cancer and other complications in postmenopausal women from 3 months to 3 years after mild burn injury.
{"title":"Estrogen Treatment Lowers the Risk of Complications in Menopausal Women with Mild Burn Injury.","authors":"Juquan Song, George Golovko, Kostiantyn Botnar, Amina El Ayadi, Kathleen L Vincent, Steven E Wolf","doi":"10.3390/medicina61020300","DOIUrl":"10.3390/medicina61020300","url":null,"abstract":"<p><p><i>Background and Objectives</i>: Postmenopausal women are often treated with exogenous female hormones to alleviate physical symptoms and support mental health. We posit that women treated with estrogen fare better following burn injury. <i>Materials and Methods</i>: De-identified patient data were obtained from TriNetX, a global healthcare research network. Adult postmenopausal women were enrolled if they were diagnosed with burn injury within 10 years after menopause onset. Patients with pre-existing abnormal uterine bleeding, gynecologic cancer, and chronic liver or heart disease were excluded. The population was grouped into those who received and those who did not receive estrogen treatment (ET) for evaluation of subsequent complications. Cohort balancing was performed using the exact match approach of Inverse Probability Treatment Weighting (IPTW). The average treatment effects (ATEs) and confidence intervals were computed for these balanced cohorts. <i>Results</i>: Postmenopausal women with ET had a lower risk of endometrial hyperplasia and malignancy 3 months (ATE = -0.005, -0.006) and 3 years (-0.007, -0.008) after mild burn injury (less than 20% of total body surface area) (<i>p</i> < 0.05), regardless of age. At the 3-month timepoint, postmenopausal women aged 45-65 with ET exhibited preventive effects against acute kidney injury (-0.0332), cerebral infarction (-0.0279), breast cancer (-0.0278) and severe sepsis (-0.011) after mild burn injury (<i>p</i> < 0.05) compared to women who did not receive ET. After 3 years, 45-65-year-old women with ET exhibited decreased rates of breast cancer (-0.0479) and endometrial hyperplasia (-0.0116) (<i>p</i> < 0.05) compared to those without ET. <i>Conclusions</i>: Estrogen treatment decreases the risk probabilities of breast cancer and other complications in postmenopausal women from 3 months to 3 years after mild burn injury.</p>","PeriodicalId":49830,"journal":{"name":"Medicina-Lithuania","volume":"61 2","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11857297/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143505637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-08DOI: 10.3390/medicina61020297
Mohamed S Imam, Dina Meshari Abdularhman Alnaim, Renad Khalid Abdullah Alaraifi, Juman Salah Saleh Alabduljabbar, Alanoud Abdulrahman Mohammed Alhamed, Asalah Mohammed Fayadh Alansari, Raghad Abdullah Ali Alqarni, Shouq Fahad Saleh Alotaibi, Dimah Zuwayyid Aali Alsufyani, Rana Mohammed Abdullah Alzaidi, Shahad Ali Hussain Mathkoor, Rawabi Hameed Hamde Alotaibi, Mohamed E A Abdelrahim, Basma M E Mohamed
Background and Objectives: A meta-analysis was conducted to assess the probable association of hypertension during pregnancy and placenta accreta (PA). Materials and Methods: A systematic literature search was conducted up to November 2024, resulting in the identification of 10 studies encompassing 128,589 pregnant women. They reported associations between the possible impacts of hypertension during pregnancy and PA. The odds ratio (OR), with 95% confidence intervals (CIs), was computed to evaluate the possible association of hypertension during pregnancy and PA, utilizing a dichotomous approach with either a random or fixed-effect model. Results: No significant difference was found between hypertension during pregnancy and control (no hypertension during pregnancy) in the occurrence of PA (OR, 0.74; 95% CI, 0.52-1.04, p = 0.08). Also, no significant difference was found between pregnant women with PA and control (no PA) in the occurrence of hypertension (OR, 1.15; 95% CI, 0.61-2.19, p = 0.66). Conclusions: Hypertension during pregnancy has no impact on the occurrence of PA, and vice versa. More research is desired to approve these outcomes.
{"title":"A Meta-Analysis to Assess the Probable Association of Hypertension During Pregnancy and Placenta Accreta.","authors":"Mohamed S Imam, Dina Meshari Abdularhman Alnaim, Renad Khalid Abdullah Alaraifi, Juman Salah Saleh Alabduljabbar, Alanoud Abdulrahman Mohammed Alhamed, Asalah Mohammed Fayadh Alansari, Raghad Abdullah Ali Alqarni, Shouq Fahad Saleh Alotaibi, Dimah Zuwayyid Aali Alsufyani, Rana Mohammed Abdullah Alzaidi, Shahad Ali Hussain Mathkoor, Rawabi Hameed Hamde Alotaibi, Mohamed E A Abdelrahim, Basma M E Mohamed","doi":"10.3390/medicina61020297","DOIUrl":"10.3390/medicina61020297","url":null,"abstract":"<p><p><i>Background and Objectives</i>: A meta-analysis was conducted to assess the probable association of hypertension during pregnancy and placenta accreta (PA). <i>Materials and Methods</i>: A systematic literature search was conducted up to November 2024, resulting in the identification of 10 studies encompassing 128,589 pregnant women. They reported associations between the possible impacts of hypertension during pregnancy and PA. The odds ratio (OR), with 95% confidence intervals (CIs), was computed to evaluate the possible association of hypertension during pregnancy and PA, utilizing a dichotomous approach with either a random or fixed-effect model. <i>Results</i>: No significant difference was found between hypertension during pregnancy and control (no hypertension during pregnancy) in the occurrence of PA (OR, 0.74; 95% CI, 0.52-1.04, <i>p</i> = 0.08). Also, no significant difference was found between pregnant women with PA and control (no PA) in the occurrence of hypertension (OR, 1.15; 95% CI, 0.61-2.19, <i>p</i> = 0.66). <i>Conclusions</i>: Hypertension during pregnancy has no impact on the occurrence of PA, and vice versa. More research is desired to approve these outcomes.</p>","PeriodicalId":49830,"journal":{"name":"Medicina-Lithuania","volume":"61 2","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11857358/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143505764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-08DOI: 10.3390/medicina61020292
Olga Vasiliauskienė, Dovydas Vasiliauskas, Aušrinė Kontrimienė, Lina Jaruševičienė, Ida Liseckienė
Background and Objectives: Despite the critical importance of effective healthcare management for patients with multimorbidity, robust and reliable tools for assessing health-related quality of life in Lithuania remain scarce. We aim to identify trends in the quality of life of patients with multimorbidity and to evaluate the effectiveness of the Lithuanian version of the EuroQol EQ-5D-5L questionnaire. Materials and Methods: The study included patients between the ages of 40 and 85 (N = 498) who had at least two chronic conditions, arterial hypertension being a prerequisite. The participants completed a comprehensive set of questionnaires specifically prepared for the TELELISPA "Improved healthcare quality for patients with multimorbidity in Lithuania" project which included the translated EQ-5D-5L questionnaire. The predictive validity of the EQ-5D-5L questionnaire was assessed using correlations with the SF-36 and EQ-VAS scores, a random forest regression model. Reliability was evaluated using Cronbach's alpha and inter-item correlations. Trends in the quality of life in different patient groups were assessed with Chi-square tests. Results: The EQ-5D-5L questionnaire demonstrated high reliability and validity with a Cronbach's alpha value of 0.737, EQ-5D-5L random forest machine learning regression model RMSE value of 0.1396, and adequate scores from other measures. Lower quality of life was found in patients with multimorbidity who had chronic conditions such as angina pectoris, heart failure, atrial fibrillation, or joint diseases, as well as the patients who were older than 60 years of age, women, or unemployed. Different aspects of quality of life were also significantly negatively impacted by diabetes, asthma, and chronic kidney disease. Heart failure, joint diseases, and older age had the biggest negative effect on quality of life. Conclusions: It is found that the Lithuanian EQ-5D-5L questionnaire is suitable for the assessment of the quality of life in patients with multimorbidity and indicates lower quality of life among those with specific cardiovascular and joint disorder chronic conditions and, in particular, demographic groups.
{"title":"Assessment of Quality of Life in Lithuanian Patients with Multimorbidity Using the EQ-5D-5L Questionnaire.","authors":"Olga Vasiliauskienė, Dovydas Vasiliauskas, Aušrinė Kontrimienė, Lina Jaruševičienė, Ida Liseckienė","doi":"10.3390/medicina61020292","DOIUrl":"10.3390/medicina61020292","url":null,"abstract":"<p><p><i>Background and Objectives</i>: Despite the critical importance of effective healthcare management for patients with multimorbidity, robust and reliable tools for assessing health-related quality of life in Lithuania remain scarce. We aim to identify trends in the quality of life of patients with multimorbidity and to evaluate the effectiveness of the Lithuanian version of the EuroQol EQ-5D-5L questionnaire. <i>Materials and Methods</i>: The study included patients between the ages of 40 and 85 (N = 498) who had at least two chronic conditions, arterial hypertension being a prerequisite. The participants completed a comprehensive set of questionnaires specifically prepared for the TELELISPA \"Improved healthcare quality for patients with multimorbidity in Lithuania\" project which included the translated EQ-5D-5L questionnaire. The predictive validity of the EQ-5D-5L questionnaire was assessed using correlations with the SF-36 and EQ-VAS scores, a random forest regression model. Reliability was evaluated using Cronbach's alpha and inter-item correlations. Trends in the quality of life in different patient groups were assessed with Chi-square tests. <i>Results</i>: The EQ-5D-5L questionnaire demonstrated high reliability and validity with a Cronbach's alpha value of 0.737, EQ-5D-5L random forest machine learning regression model RMSE value of 0.1396, and adequate scores from other measures. Lower quality of life was found in patients with multimorbidity who had chronic conditions such as angina pectoris, heart failure, atrial fibrillation, or joint diseases, as well as the patients who were older than 60 years of age, women, or unemployed. Different aspects of quality of life were also significantly negatively impacted by diabetes, asthma, and chronic kidney disease. Heart failure, joint diseases, and older age had the biggest negative effect on quality of life. <i>Conclusions</i>: It is found that the Lithuanian EQ-5D-5L questionnaire is suitable for the assessment of the quality of life in patients with multimorbidity and indicates lower quality of life among those with specific cardiovascular and joint disorder chronic conditions and, in particular, demographic groups.</p>","PeriodicalId":49830,"journal":{"name":"Medicina-Lithuania","volume":"61 2","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11857477/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143505539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-08DOI: 10.3390/medicina61020294
Filippo Migliorini, Ludovico Lucenti, Ying Ren Mok, Tommaso Bardazzi, Riccardo D'Ambrosi, Angelo De Carli, Domenico Paolicelli, Nicola Maffulli
Background and Objectives: The present systematic review investigated the efficacy of lateral extra-articular tenodesis (LET) and anterolateral ligament (ALL) as lateral extra-articular procedures (LEAPs) for anterior cruciate ligament (ACL) reconstruction. ACL reconstruction using LEAP may reduce graft rupture and rotatory laxity and allow a quicker return to sports. The outcomes of interest were patient-reported outcome measures (PROMs), return to sport, laxity, failure rate, and safety profile. Materials and Methods: The present systematic review followed the 2020 PRISMA guidelines. In December 2024, PubMed, EMBASE, and Web of Science were accessed without constraints. All clinical investigations evaluating LEAP for ACL reconstruction were considered. Only studies that considered LET and ALL as LEAP were considered. Only studies using a hamstring tendon autograft associated with LET or ALL were considered. Results: Data from 27 clinical studies (3423 patients) were retrieved. The mean length of follow-up was 61.8 ± 39.5 months. ACL reconstruction using LEAP led to a statistically significant improvement in the Lysholm score (p < 0.01) and IKDC (p < 0.01). The mean joint laxity, as measured by the arthrometer, was 1.5 ± 1.8 mm. Finally, 72.3% (623 of 668) of patients returned to their pre-injury level of sport at a mean of 6.3 ± 4.4 months. At the last follow-up, the LET group showed greater IKDC (p = 0.04). On the other hand, there was a statistically significant greater rate of patients positive to the Lachman test (p < 0.01), return to sport (p < 0.01), and reoperation (p = 0.01). No significant differences were found in Lysholm scores (p = 0.6), Tegner scores (p = 0.2), arthrometer measurements (p = 0.2), Pivot shift test results (p = 0.1), time to return to sport (p = 0.3), and failure rates (p = 0.7). Conclusions: LEAP for ACL reconstructions seems to be effective and safe. Most patients returned to their pre-injury level of sport after a mean of 6 months. LET-based ACL reconstruction may be associated with greater clinical outcomes and a higher reoperation rate compared to ALL-based reconstruction.
{"title":"Anterior Cruciate Ligament Reconstruction Using Lateral Extra-Articular Procedures: A Systematic Review.","authors":"Filippo Migliorini, Ludovico Lucenti, Ying Ren Mok, Tommaso Bardazzi, Riccardo D'Ambrosi, Angelo De Carli, Domenico Paolicelli, Nicola Maffulli","doi":"10.3390/medicina61020294","DOIUrl":"10.3390/medicina61020294","url":null,"abstract":"<p><p><i>Background and Objectives</i>: The present systematic review investigated the efficacy of lateral extra-articular tenodesis (LET) and anterolateral ligament (ALL) as lateral extra-articular procedures (LEAPs) for anterior cruciate ligament (ACL) reconstruction. ACL reconstruction using LEAP may reduce graft rupture and rotatory laxity and allow a quicker return to sports. The outcomes of interest were patient-reported outcome measures (PROMs), return to sport, laxity, failure rate, and safety profile. <i>Materials and Methods</i>: The present systematic review followed the 2020 PRISMA guidelines. In December 2024, PubMed, EMBASE, and Web of Science were accessed without constraints. All clinical investigations evaluating LEAP for ACL reconstruction were considered. Only studies that considered LET and ALL as LEAP were considered. Only studies using a hamstring tendon autograft associated with LET or ALL were considered. <i>Results</i>: Data from 27 clinical studies (3423 patients) were retrieved. The mean length of follow-up was 61.8 ± 39.5 months. ACL reconstruction using LEAP led to a statistically significant improvement in the Lysholm score (<i>p</i> < 0.01) and IKDC (<i>p</i> < 0.01). The mean joint laxity, as measured by the arthrometer, was 1.5 ± 1.8 mm. Finally, 72.3% (623 of 668) of patients returned to their pre-injury level of sport at a mean of 6.3 ± 4.4 months. At the last follow-up, the LET group showed greater IKDC (<i>p</i> = 0.04). On the other hand, there was a statistically significant greater rate of patients positive to the Lachman test (<i>p</i> < 0.01), return to sport (<i>p</i> < 0.01), and reoperation (<i>p</i> = 0.01). No significant differences were found in Lysholm scores (<i>p</i> = 0.6), Tegner scores (<i>p</i> = 0.2), arthrometer measurements (<i>p</i> = 0.2), Pivot shift test results (<i>p</i> = 0.1), time to return to sport (<i>p</i> = 0.3), and failure rates (<i>p</i> = 0.7). <i>Conclusions</i>: LEAP for ACL reconstructions seems to be effective and safe. Most patients returned to their pre-injury level of sport after a mean of 6 months. LET-based ACL reconstruction may be associated with greater clinical outcomes and a higher reoperation rate compared to ALL-based reconstruction.</p>","PeriodicalId":49830,"journal":{"name":"Medicina-Lithuania","volume":"61 2","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11857574/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143505313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-08DOI: 10.3390/medicina61020291
Hüseyin Demirtaş, Abdullah Özer, Alperen Kutay Yıldırım, Ali Doğan Dursun, Şaban Cem Sezen, Mustafa Arslan
Background and Objectives: Ischemia-reperfusion (I/R) injury can affect multiple distant organs following I/R in the lower extremities. BPC-157's anti-inflammatory and free radical-neutralizing properties suggest its potential in mitigating ischemia-reperfusion damage. This study evaluates the protective effects of BPC-157 on remote organ damage, including the kidneys, liver, and lungs, in a rat model of skeletal muscle I/R injury. Materials and Methods: A total of 24 male Wistar albino rats were randomly divided into four groups: sham (S), BPC-157(B), lower extremity I/R(IR) and lower extremity I/R+BPC-157(I/RB). Some 45 min of ischemia of lower extremity was followed by 2 h of reperfusion of limbs. BPC-157 was applied to groups B and I/RB at the beginning of the procedure. After 2 h of reperfusion, liver, kidney and lung tissues were harvested for biochemical and histopathological analyses. Results: In the histopathological examination, vascular and glomerular vacuolization, tubular dilation, hyaline casts, and tubular cell shedding in renal tissue were significantly lower in the I/RB group compared to other groups. Lung tissue showed reduced interstitial edema, alveolar congestion, and total damage scores in the I/RB group. Similarly, in liver tissue, sinusoidal dilation, necrotic cells, and mononuclear cell infiltration were significantly lower in the I/RB group. Additionally, the evaluation of TAS, TOS, OSI, and PON-1 revealed a statistically significant increase in antioxidant activity in the liver, lung, and kidney tissues of the I/RB group. Conclusions: The findings of this study demonstrate that BPC-157 exerts a significant protective effect against distant organ damage in the liver, kidneys, and lungs following lower extremity ischemia-reperfusion injury in rats.
{"title":"Protective Effects of BPC 157 on Liver, Kidney, and Lung Distant Organ Damage in Rats with Experimental Lower-Extremity Ischemia-Reperfusion Injury.","authors":"Hüseyin Demirtaş, Abdullah Özer, Alperen Kutay Yıldırım, Ali Doğan Dursun, Şaban Cem Sezen, Mustafa Arslan","doi":"10.3390/medicina61020291","DOIUrl":"10.3390/medicina61020291","url":null,"abstract":"<p><p><i>Background and Objectives</i>: Ischemia-reperfusion (I/R) injury can affect multiple distant organs following I/R in the lower extremities. BPC-157's anti-inflammatory and free radical-neutralizing properties suggest its potential in mitigating ischemia-reperfusion damage. This study evaluates the protective effects of BPC-157 on remote organ damage, including the kidneys, liver, and lungs, in a rat model of skeletal muscle I/R injury. <i>Materials and Methods</i>: A total of 24 male Wistar albino rats were randomly divided into four groups: sham (S), BPC-157(B), lower extremity I/R(IR) and lower extremity I/R+BPC-157(I/RB). Some 45 min of ischemia of lower extremity was followed by 2 h of reperfusion of limbs. BPC-157 was applied to groups B and I/RB at the beginning of the procedure. After 2 h of reperfusion, liver, kidney and lung tissues were harvested for biochemical and histopathological analyses. <i>Results</i>: In the histopathological examination, vascular and glomerular vacuolization, tubular dilation, hyaline casts, and tubular cell shedding in renal tissue were significantly lower in the I/RB group compared to other groups. Lung tissue showed reduced interstitial edema, alveolar congestion, and total damage scores in the I/RB group. Similarly, in liver tissue, sinusoidal dilation, necrotic cells, and mononuclear cell infiltration were significantly lower in the I/RB group. Additionally, the evaluation of TAS, TOS, OSI, and PON-1 revealed a statistically significant increase in antioxidant activity in the liver, lung, and kidney tissues of the I/RB group. <i>Conclusions</i>: The findings of this study demonstrate that BPC-157 exerts a significant protective effect against distant organ damage in the liver, kidneys, and lungs following lower extremity ischemia-reperfusion injury in rats.</p>","PeriodicalId":49830,"journal":{"name":"Medicina-Lithuania","volume":"61 2","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11857380/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143505711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-08DOI: 10.3390/medicina61020293
Alicja Dudek, Barbara Zapała, Aleksandra Gorostowicz, Ilona Kawa, Karol Ciszek, Piotr Tylec, Katarzyna Cyranka, Wojciech Sierocki, Michał Wysocki, Piotr Major
Background and Objectives: The relationships between aging, chronic diseases, and obesity remain complex and poorly understood. This study aimed to investigate the impact of comorbidities on premature aging in individuals with severe obesity. Materials and Methods: This cross-sectional study included 99 bariatric patients with severe obesity (SG) and 30 healthy volunteers (HC). SG was further divided into subgroups based on comorbidity status. Various markers of biological aging, including interleukin-6 (IL-6), C-reactive protein (CRP), telomere length (TL), attention speed, executive functions, and metabolic age, were evaluated. Results: Both subgroups of patients with obesity presented elevated levels of IL-6 and CRP, shorter TLs, lower outcomes in executive functioning tests, and greater metabolic age than healthy subjects. However, no significant differences were observed between patients with obesity with and without comorbidities. This study highlighted the impact of BMI on increased inflammation and revealed that hypertension and inflammation are associated with cognitive decline. Conclusions: These findings suggest that obesity, regardless of comorbidities, contributes to premature aging. The presence of hypertension was linked to cognitive function decline, emphasizing the multifaceted implications of obesity for the aging process.
{"title":"What Is the Impact of Obesity-Related Comorbidities on the Risk of Premature Aging in Patients with Severe Obesity?: A Cross-Sectional Study.","authors":"Alicja Dudek, Barbara Zapała, Aleksandra Gorostowicz, Ilona Kawa, Karol Ciszek, Piotr Tylec, Katarzyna Cyranka, Wojciech Sierocki, Michał Wysocki, Piotr Major","doi":"10.3390/medicina61020293","DOIUrl":"10.3390/medicina61020293","url":null,"abstract":"<p><p><i>Background and Objectives</i>: The relationships between aging, chronic diseases, and obesity remain complex and poorly understood. This study aimed to investigate the impact of comorbidities on premature aging in individuals with severe obesity. <i>Materials and Methods</i>: This cross-sectional study included 99 bariatric patients with severe obesity (SG) and 30 healthy volunteers (HC). SG was further divided into subgroups based on comorbidity status. Various markers of biological aging, including interleukin-6 (IL-6), C-reactive protein (CRP), telomere length (TL), attention speed, executive functions, and metabolic age, were evaluated. <i>Results</i>: Both subgroups of patients with obesity presented elevated levels of IL-6 and CRP, shorter TLs, lower outcomes in executive functioning tests, and greater metabolic age than healthy subjects. However, no significant differences were observed between patients with obesity with and without comorbidities. This study highlighted the impact of BMI on increased inflammation and revealed that hypertension and inflammation are associated with cognitive decline. <i>Conclusions</i>: These findings suggest that obesity, regardless of comorbidities, contributes to premature aging. The presence of hypertension was linked to cognitive function decline, emphasizing the multifaceted implications of obesity for the aging process.</p>","PeriodicalId":49830,"journal":{"name":"Medicina-Lithuania","volume":"61 2","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11857414/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143505803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}